Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02247453 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Plasma microRNA Profiling as First Line Screening Test for Lung Cancer Detection: a Prospective Study

Study acronym: BIOMILD
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor Re-verified, no change to tracked fieldsv12
  2. Minor Study completion date: Oct 2022 to Oct 2026v11
  3. Minor Study completion date: Mar 2022 to Oct 2022v10
  4. Minor Study completion date: Sep 2021 to Mar 2022v9
  5. Minor Re-verified, no change to tracked fieldsv8
Show 6 earlier versionsHide 6 earlier versions
  1. Minor Primary completion date changed from estimate of Sep 2019 to Nov 2019v7
  2. Minor Primary completion date: May 2019 to Sep 2019
    • Study completion date: May 2021 to Sep 2021
    v6
  3. Minor Primary completion date: Jan 2019 to May 2019
    • Study completion date: Jan 2021 to May 2021
    v5
  4. Notable Phase: Phase 3 to Not applicable
    • Primary completion date: Jan 2018 to Jan 2019
    • Study completion date: Jan 2018 to Jan 2021
    v4
  5. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 4000 to confirmed 4119
    • Site details revised
    v3
  6. Notable Primary completion date: Jan 2015 to Jan 2018
    • Publications: 10 to 12
    v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In the present project we propose a large prospective study in heavy smokers volunteers based on plasma miRNA profiling to assess its efficacy as a first line screening test for lung cancer detection. The study will be articulated in different phases: i) analysis of 1000 plasma samples of disease-free smokers already collected in our biological repository in the last two years ii) de-novo enrollment of 4000 smoking volunteers, collection of their blood samples and inclusion in a program of active surveillance on the basis of their miRNA risk profile iii) assessment of miRNA expression profile using a custom made microfluidic card containing the 24 miRNA previously identified in the diagnostic signatures iii) bioinformatic analyses of miRNA ratios in the cohort in order to determine which individuals are in presence or will develop lung cancer and in particular the aggressive form of the disease iv) assessment of the best diagnostic and treatment algorithm for subjects with suspicious miRNA profiles v) functional validation of miRNAs as novel therapeutic targets using novel cellular genetically engineered models of transformation and patients' tumorgrafts models.
Trial Details
NCT Number NCT02247453
Lead Sponsor Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Conditions
(from sponsor)
Lung Cancer
Related terms Lung Neoplasms
Enrollment 4,119 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov